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Abstract: 
Many respiratory diseases of chickens undergo airway contraction from edema, 
the formation of mucus, and cellular penetration. Based on the natural breath by 
breath system sometimes the normal amount of air may not flow easily. So the 
airways may vulnerable to failure. That leads to the common symptoms of the 
disease such as noisy breathing, cough, lethargy, and sneeze. Therefore, 
mucolytic drug therapy (bromhexine) is one of the options to increase the 
diameter of the airway that may mitigate or even eliminate these clinical signs. 
Hence the objective of this study is to review the literature regarding the use of 
bromhexine for the prevention and treatment of respiratory diseases. 
Keywords: Respiratory diseases, chickens, mucus, disease symptoms, 
bromhexine. 
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INTRODUCTION 
Within the increasing population of the 
world the demand for poultry protein is 
increasing day by day (Butt et al., 2016; Hadyait 
et al., 2018). Respiratory infections in poultry are 
the major group of diseases that cause 
significant economic losses to the poultry 
industry (Baksi et al., 2017). Now a day the 
tremendous growth of the poultry industry makes 
it more susceptible to respiratory diseases 
(Ashraf et al., 2019). So different chemical 
compounds in form of veterinary drugs with the 
object of preventing and treating animals 
including poultry birds from respiratory diseases 
have been used (Davidson et al., 2008; Sumano 
and Gutierrez, 2008).  
Self-defense mechanism against viruses and 
bacteria  
In response to airborne disease agents, 
the poultry respiratory tract acts as a self-
immune defense. There are three defensive 
mechanisms (cilia, mucus secretions, and 
scavenging cells) that protect poultry respiratory 
health. Cilia are hair-like structures in the 
trachea of poultry birds that are engaged in 
pushing the trapped particles. There are some 
goblet cells in the trachea that produce mucus. 
Mucus is composed of 95% water and 2% 
glycoprotein that is enriched in sialic acid (Cottel, 
1995). The uniformity of the production of mucus 
in the trachea is vital for the better activity of 
cilia. At the submucosal level, the goblet cells 
produce more components of fluids along with a 
lesser concentration of glycoprotein (Bartoll, 
2002). It has also been observed that the 
production of more viscosity of the mucus is due 
to bacterial or viral infection. Actually, in a 
common cold environment the rhinovirus, 
coronavirus, and adenovirus cause infection in 
the upper respiratory tract (Schellack and 
Labuschagne, 2014). And that the virus 
damages the ciliated cells that lead to the 
release of inflammatory mediators that causes 
the inflammation of linings of nasal tissues. 
Along with the increased permeability of capillary 
cell walls undergoes edema. Whereas the 
edema is responsible for coughing, sneezing, 
fever, sore throat, and congestion (Schellack 
and Labuschagne, 2014: National Prescribing 
Centre, 2017). But in recent studies, it has been 
known that bromhexine acts as an antioxidant 
and anti-inflammatory agent (Gibbs et al., 1999) 
against rhinovirus, coronavirus, adenovirus, and 
many other bacteria. Whereas the scavenging 
cells in the lungs engulf the bacteria and inhaled 
particles. The air within unnecessary dusting 
produces the tracheal plugs that are unfavorable 
for the health of chickens. It has been noted that 
the production of ammonia from 10 to 40 ppm 
increased the excessive mucus that damage the 
cilia (Jacob and Pescatore, 2017). 
Introduction of Bromhexine  
To get rid of these respiratory diseases 
different mucolytic agents (bromhexine and 
ambroxol) are used in poultry farming. These 
bromhexine and ambroxol medicinal products 
were first time registered in European Union 
Member State in 1963 and 1978 respectively 
and recently used in European Union Member 
State (Debuf, 1991). Along with these mucolytic 
drugs (bromhexine, ambroxol, carbocysteine, 
and ethylenediamine) are abundantly used in 
poultry farming (Lizbeth et al., 2016). 
Bromhexine is a kind of cough related 
medicine having structural formula Br-CH2-CH2-
CH2-CH2-CH2-CH3 (NCBI, 2019). Bromhexine 
and its metabolites such as ambroxol and 
cyclohexanol hydrochloride have been 
abundantly used in the poultry industry because 
of their mucolytic characteristics in the treatment 
of respiratory-related problems such as cystic 
fibrosis and chronic obstructive airway disease 
(Mestorino et al., 2011). The mucolytic drugs are 
mostly used with the antibiotics for the treatment 
of respiratory diseases to increase the 
elimination of excessive persistent mucus 
(Debuf, 1991; Bottje et al., 1998). So that the low 
viscosity mucus can easily be removed during 
coughing. Whereas Garst et al. (1991) stated 
that it is used to produce natural chemicals that 
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are engaged in the manufacturing of Bromo-
cyclic compounds.  
It is always preferable to use the drugs 
within the water. As the birds drink water at that 
time when the birds do not eat (Debuf, 1991). 
The advantage of the use of waterborne drugs is 
that these reduce the spread of disease by the 
contamination of water with the drugs (Clubb, 
1984). 
Absorption and the action mechanism of 
bromhexine in poultry  
Oral supplementation of bromhexine is 
absorbed in the GIT (gastrointestinal tract) and 
it’s wide metabolism is started in the liver. Just 
within one hour about 20% bromhexine from the 
liver is disseminated into the body tissues and 
attached to the plasma proteins (Reynolds, 
2002). Whereas in lungs the bromhexine 
destroys the composition of acid 
mucopolysaccharide fibers and remove the 
mucus (thick liquid) by converting it into less 
thick liquid from the lungs. The remaining dose 
of about 85% to 90% bromhexine is removed 
through the urine (Lund, 1994; Morton et al., 
1999). However, the mechanism of action of 
bromhexine has been moderately investigated.  
Some of its actions have been examined that 
control the production of mucosubstances, 
sputum quality, and quantity, ciliary activity, 
diffusion of antibiotics and brutality, and 
regularity of cough. These characteristics 
discriminate it from other diseases (Alessandro 
et al., 2017).  
Effect of bromhexine on the antibiotic 
penetration  
Bromhexine can be used for the cure of 
respiratory diseases in amalgamation with 
antimicrobial agents. It destroys the 
mucopolysaccharides of bronchial secretion and 
enhances the saturation of antimicrobial drugs 
(Mestorino et al., 2011). These agents are 
currently used as a therapy for the destruction of 
pathogens. For example, in the case of alcoholic 
chronic pancreatitis where the viscosity of 
pancreatic juice is increased (Tscimoto et al., 
2004). Furthermore, bromhexine HCl increases 
the bronchial dissemination of antimicrobial 
drugs and thus interrupt the 
mucopolysaccharides of the bronchial secretions 
(Bergogne et al., 1985). It has been described 
that the bromhexine hydrochloride enhanced the 
concentration of oxytetracycline in the secreted 
mucus (Bergogne, 1985; Martin et al., 1993) and 
that it also starts the reverse reaction of 
mucolytic activity of oxytetracycline in vivo 
(Martin et al., 1993). So it is possible to assume 
that bromhexine is a mucolytic agent that 
introduces changes in the tracheobronchial 
secretions. However further work on bromhexine 
is required for the treatment of respiratory 
diseases in poultry birds.  
 
CONCLUSION 
Although from previous studies the 
practical facts related to the poultry field indicate 
only reticent and positive results, it is not 
denotable that the efficiency of bromhexine is 
arguable. Bromhexine within a very minute 
occurrence of placid side effects is associated 
with positive perfection in the clearance of 
mucus from respiratory disease birds. There are 
inadequate facts in the literature to sustain the 
use of bromhexine for the prevention and 
treatment of these respiratory diseases. 
Bromhexine is currently used as a medicinal 
therapy for the removal of mucus produced by 
the infection of bacterial and viral pathogens. 
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